Compare
Black Diamond Therapeutics, Inc. vs Vir Biotechnology, Inc. vs Recursion Pharmaceuticals, Inc. vs Autolus Therapeutics plc
| Latest fiscal year | Black Diamond Therapeutics, Inc. BDTX | Vir Biotechnology, Inc. VIR | Recursion Pharmaceuticals, Inc. RXRX | Autolus Therapeutics plc AUTL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $70.00M | $68.56M | $74.68M | $75.39M |
| Revenue growth (YoY) | n/a | -7.6% | +26.9% | +644.9% |
| Gross margin | n/a | n/a | 5.0% (computed) | -27.8% (computed) |
| Operating margin | 17.9% | -699.2% | -867.9% | -358.9% |
| Net margin | 32.0% | -638.9% | -863.4% | -381.4% |
| Net income | $22.37M | -$437.99M | -$644.76M | -$287.53M |
| EPS (Diluted) | $0.39 | -$3.16 | -$1.44 | -$1.08 |
| Operating cash flow | $29.61M | -$391.78M | -$371.81M | -$283.57M |
| Free cash flow | n/a | -$396.61M | -$378.28M | -$302.61M |
| Cash & equivalents | $20.99M | $232.19M | $743.29M | $104.13M |
| Total assets | $143.01M | $1.00B | $1.47B | $589.07M |
| Total liabilities | $30.80M | $237.55M | $343.26M | $410.94M |
| Shareholders' equity | $112.21M | $765.28M | $1.13B | $178.13M |
| Return on year-end equity | 19.9% | -57.2% | -57.0% | -161.4% |
| Shares outstanding | 57.14M | 139.47M | 528.18M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Black Diamond Therapeutics, Inc. | Vir Biotechnology, Inc. | Recursion Pharmaceuticals, Inc. | Autolus Therapeutics plc |
|---|---|---|---|---|
| Latest | $70.00M Ended 2025-12-31 | $68.56M Ended 2025-12-31 | $74.68M Ended 2025-12-31 | $75.39M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $74.20M Ended 2024-12-31 | $58.84M Ended 2024-12-31 | $10.12M Ended 2024-12-31 |
| 2 years earlier | n/a | $86.18M Ended 2023-12-31 | $44.58M Ended 2023-12-31 | $1.70M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.62B Ended 2022-12-31 | $39.84M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $1.10B Ended 2021-12-31 | $10.18M Ended 2021-12-31 | n/a |